LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

Inicio・Lista de Acciones・Gossamer Bio Inc

Gossamer Bio Inc

Cerrado

SectorSanidad

0.2 17.65

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

0.19

Máximo

0.22

Métricas clave
By Trading Economics
Ingresos	574K -47M
Ventas	3.2M 17M
BPA	-0.2
Margen de beneficios	-275.223
Empleados	161
EBITDA	947K -45M

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 Meses	+2336.84% upside

Dividendos
By Dow Jones
Próximas Ganancias	3 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-34M 45M
Apertura anterior	-17.45
Cierre anterior	0.2

Noticias sobre sentimiento de mercado

By Acuity

72%

28%

290 / 345 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

1.06 / 1.23 Soporte y Resistencia

Gossamer Bio Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

19 may 2026, 20:36 UTC

Adquisiciones, fusiones, absorciones

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

19 may 2026, 23:47 UTC

Charlas de Mercado

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

19 may 2026, 23:34 UTC

Charlas de Mercado

Gold Edges Higher on Possible Technical Recovery -- Market Talk

19 may 2026, 23:28 UTC

Charlas de Mercado

Ganancias

Global Forex and Fixed Income Roundup: Market Talk

19 may 2026, 23:28 UTC

Charlas de Mercado

Ganancias

F&P Healthcare's Outlook Key for Investors -- Market Talk

19 may 2026, 23:10 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

19 may 2026, 23:10 UTC

Charlas de Mercado

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

19 may 2026, 22:02 UTC

Ganancias

ZTO Express (Cayman): Di Xu to Resign From Board

19 may 2026, 22:01 UTC

Ganancias

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

19 may 2026, 22:01 UTC

Ganancias

ZTO Express (Cayman) 1Q EPS 39c >ZTO

19 may 2026, 22:00 UTC

Ganancias

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

19 may 2026, 21:37 UTC

Ganancias

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

19 may 2026, 21:31 UTC

Adquisiciones, fusiones, absorciones

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

19 may 2026, 21:01 UTC

Ganancias

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

19 may 2026, 20:58 UTC

Ganancias

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

19 may 2026, 20:46 UTC

Acciones populares

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

19 may 2026, 20:43 UTC

Charlas de Mercado

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

19 may 2026, 20:34 UTC

Ganancias

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

19 may 2026, 20:32 UTC

Ganancias

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

19 may 2026, 20:32 UTC

Ganancias

James Hardie Industries 4Q EPS 5c >JHX

19 may 2026, 20:32 UTC

Ganancias

James Hardie Industries 4Q Sales $1.4B >JHX

19 may 2026, 20:21 UTC

Adquisiciones, fusiones, absorciones

Analog Devices to Buy Empower Semiconductor for $1.5B

19 may 2026, 20:18 UTC

Charlas de Mercado

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

19 may 2026, 20:13 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

19 may 2026, 20:13 UTC

Charlas de Mercado

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

19 may 2026, 20:03 UTC

Adquisiciones, fusiones, absorciones

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

19 may 2026, 20:03 UTC

Adquisiciones, fusiones, absorciones

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

19 may 2026, 20:02 UTC

Adquisiciones, fusiones, absorciones

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

19 may 2026, 20:02 UTC

Adquisiciones, fusiones, absorciones

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

19 may 2026, 19:23 UTC

Charlas de Mercado

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Comparación entre iguales

Cambio de precio

Gossamer Bio Inc previsión

Precio Objetivo

By TipRanks

2336.84% repunte

Estimación a 12 Meses

Media 4.63 USD 2336.84%

Máximo 15 USD

Mínimo 0.28 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Gossamer Bio Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

8 ratings

Comprar

Mantener

Vender

De acuerdo con 8 analistas que ofrecen calificaciones bursátiles a para Gossamer Bio Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.06 / 1.23Soporte y Resistencia

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentimiento

By Acuity

290 / 345 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.